HAHellen Regina Oliveira de Almeida

Hellen Regina Oliveira de Almeida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hellen Regina Oliveira de Almeida has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Study of Rotigotine Release and Permeation from the Neupro® Transdermal Patch: An In Vitro-In Vivo Correlation

    by Thamara de Carvalho Mendes, Hellen Regina Oliveira de Almeida, Lucio Mendes Cabral, Alice Simon, Valeria Pereira de Sousa

    Rotigotine (RTG) is a non-ergolinic dopaminergic agonist indicated for Parkinson’s and Willis-Ekbom diseases, administered exclusively via Neupro

  • Production of biodegradable rods of polycaprolactone/olanzapine for potential application in treatment of Schizophrenia

    by Hellen Regina Oliveira de Almeida, Beatriz Ferreira de Carvalho Patricio, Yasmin Do Anjos Garcia, Talita Goulart da Silva, Debora Baptista Pereira, Michelle Alvares Sarcinelli, Helvécio Vinícius Antunes Rocha, Roberta Helena Mendonça

    Olanzapine (OLZ) is a commonly antipsychotic used to treat schizophrenia, a mental illness, with fewer side effects when compared with other drugs of the same class. It is commercialized mainly as oral tablets and orally disintegrating tablets. However, this drug oral bioavailability is affected by the first pass effect and low solubility in water. This requires high daily doses that can cause more side effects and poor treatment compliance. Also, the frequency of frequency of tablet intake is commonly related to patients' abandonment of schizophrenia treatment. So, the development of implantable biomaterials for OLZ delivery can be an alternative to solve both problems, since this material can, potentially, be used subcutaneously in less frequent administrations, thus the treatment has a greater chance of success. Therefore, the objective of this work was to produce polycaprolactone (PCL) rods incorporated with OLZ by hot‐melt extrusion technique. The rods were characterized by different techniques, which showed an amount of 6.78 ± 0.56 mg of OLZ per rod. The in vitro release studies were performed and they showed a controlled release of the drug that followed the Higuchi's model. These results indicated that the PCL/OLZ rods have potential application in the schizophrenia treatment.